Clinical characteristics of patients hospitalized to the Ukrainian expert-consultative center of pulmonary hypertension for adults

Abstract

Pulmonary arterial hypertension (PAH) is a group of rare, malignant diseases that, without optimal treatment, quickly lead to death (the average survival of patients in the absence of specific therapy is 2.8 years from diagnosis). This nosology is most often diagnosed at an earlier age and mainly in female patients. The global trend indicates a predominance of PAH in women over men in 2–4 times greater. The objective of the paper to study the condition of inpatients to determine the strategy of medical care and identify ways to improve the pharmaceutical supply of patients with pulmonary arterial hypertension. The object of the study were the results of a retrospective analysis of medical records of inpatients 93 patients hospitalized at the Ukrainian Expert-Consultative Center for Pulmonary Hypertension for Adults, established on the basis of NSC «Strazhesko Institute of Cardiology of the National Academy of Medical Sciences of Ukraine». Analytical, documentary, informational, graphic and retrospective research methods were used during the research. According to the results of a retrospective analysis of 93 medical records of inpatients who were registered and treated at the Ukrainian Expert Advisory Center for Adults for the period from 2018 to 2021, it was found that almost all patients with PAH have heart problems and other concomitant pathological conditions. The period of inpatient treatment consisted of maintenance therapy with diuretics (spironolactone, furosemide, triphas, torside, torasemide), anticoagulants (warfarin), cardiac glycosides (digoxin) and iron supplements (maltoferfol) and specific therapies using calcium channel blockers (amlodipine), prostacyclin analogues (ventavis), endothelin receptor antagonists (bosentan) and phosphodiesterase type 5 inhibitors (sildenafil, no-lag). Patients with PAH were hospitalized for 2 days to 31 days, the average number of bed-days was 8.75 days per 1 patient. Thus, the results of the study of the clinical characteristics of patients hospitalized at the Ukrainian Expert Advisory Center of Pulmonary Hypertension for Adults, indicate the need to determine the technology of specific therapy of PAH with pharmacoeconomic analysis.

Keywords

• pulmonary arterial hypertension in adults
• medical card of an inpatient
• pharmacotherapy